RTW Biotech Opportunities has a great track record which isn't reflected in a wide discount to net asset value
Since inception in October 2019 RTW Biotech Opportunities (RTW) has delivered 65.3% growth in NAV (net asset value), smashing the performance of the Russell 2000 Biotech index which is down 0.7% as well as the NBI (Nasdaq Biotech Index) which is up 20.6% over the same period.Despite the superior performance to the benchmark and peers, the shares trade at an unwarranted 23% discount to NAV, represe